The Anti-Aggregative Potential of Resolvin E1 on Human Platelets

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2023 Jul 29

PMID 37513197

Authors

Patrycja Szymanska

Boguslawa Luzak

Katarzyna Milowska

Jacek Golanski

Affiliations

Soon will be listed here.

Abstract

Resolvin E1 is a metabolite of eicosapentaenoic acid (EPA) which is one of the omega-3 polyunsaturated fatty acids (omega-3 PUFAs). The antiplatelet properties of omega-3 PUFAs are well known, but the effect of resolvin E1 on platelets via the collagen receptors is extremely poorly reported. We investigated the effect of resolvin E1 on collagen-induced platelet aggregation, activation, and reactivity, and also platelet membrane fluidity. The ultimate and statistically significant results showed that resolvin E1 may inhibit platelet reactivity due to the reduction of collagen-induced platelet aggregation in platelet-rich plasma and isolated platelets, but not in whole blood. Also, resolvin E1 significantly reduced P-selectin exposure on collagen-stimulated platelets. Moreover, we demonstrated that resolvin E1 can maintain platelet membrane structure (without increasing membrane fluidity). The association between platelet reactivity and membrane fluidity, including resolvin E1 and collagen receptors requires further research. However, the goal of this study was to shed light on the molecular mechanisms behind the anti-aggregative effects of resolvin E1 on platelets, which are still not fully clarified. We also indicate an innovative research direction focused on further analysis and then use of omega-3 PUFAs metabolites as antiplatelet compounds for future applications in the treatment and prevention of cardiovascular diseases.

Citing Articles

The Role of Endogenous Specialized Proresolving Mediators in Mast Cells and Their Involvement in Inflammation and Resolution.

Fukuishi N, Takahama K, Kurosaki H, Ono S, Asai H Int J Mol Sci. 2025; 26(4).

PMID: 40003957 PMC: 11855587. DOI: 10.3390/ijms26041491.

TRAP-Induced Platelet Reactivity Is Inhibited by Omega-3 Fatty Acid-Derived Prostaglandin E3 (PGE3).

Osete J, Garcia-Candel F, Fernandez-Gomez F, Blanquer M, Atucha N, Garcia-Estan J Biomedicines. 2025; 12(12.

PMID: 39767761 PMC: 11673155. DOI: 10.3390/biomedicines12122855.

Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease.

Fredman G, Serhan C Nat Rev Cardiol. 2024; 21(11):808-823.

PMID: 38216693 DOI: 10.1038/s41569-023-00984-x.

References

Yang X, Sheng W, Sun G, Lee J . Effects of fatty acid unsaturation numbers on membrane fluidity and α-secretase-dependent amyloid precursor protein processing. Neurochem Int. 2010; 58(3):321-9. PMC: 3040984. DOI: 10.1016/j.neuint.2010.12.004. View

Hashimoto M, Hossain S, Yamasaki H, Yazawa K, Masumura S . Effects of eicosapentaenoic acid and docosahexaenoic acid on plasma membrane fluidity of aortic endothelial cells. Lipids. 2000; 34(12):1297-304. DOI: 10.1007/s11745-999-0481-6. View

Bae J, Lim H, Lim S . The Potential Cardiometabolic Effects of Long-Chain ω-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies. Adv Nutr. 2023; 14(4):612-628. PMC: 10334139. DOI: 10.1016/j.advnut.2023.03.014. View

Wiktorowska-Owczarek A, Berezinska M, Nowak J . PUFAs: Structures, Metabolism and Functions. Adv Clin Exp Med. 2016; 24(6):931-41. DOI: 10.17219/acem/31243. View

Bray P . Platelet hyperreactivity: predictive and intrinsic properties. Hematol Oncol Clin North Am. 2007; 21(4):633-45, v-vi. PMC: 1986652. DOI: 10.1016/j.hoc.2007.06.002. View

Innes J, Calder P . Marine Omega-3 (N-3) Fatty Acids for Cardiovascular Health: An Update for 2020. Int J Mol Sci. 2020; 21(4). PMC: 7072971. DOI: 10.3390/ijms21041362. View

Vors C, Allaire J, Mejia S, Khan T, Sievenpiper J, Lamarche B . Comparing the Effects of Docosahexaenoic and Eicosapentaenoic Acids on Inflammation Markers Using Pairwise and Network Meta-Analyses of Randomized Controlled Trials. Adv Nutr. 2020; 12(1):128-140. PMC: 7850108. DOI: 10.1093/advances/nmaa086. View

Lu L, Okada N, Nakatani S, Yoshikawa K . Eicosapentaenoic acid-induced changes in membrane fluidity and cell adhesion molecules in cultured human keratinocytes. Br J Dermatol. 1995; 133(2):217-22. DOI: 10.1111/j.1365-2133.1995.tb02618.x. View

Dona M, Fredman G, Schwab J, Chiang N, Arita M, Goodarzi A . Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood. 2008; 112(3):848-55. PMC: 2481548. DOI: 10.1182/blood-2007-11-122598. View

10.

Chen Y, Zhong H, Zhao Y, Luo X, Gao W . Role of platelet biomarkers in inflammatory response. Biomark Res. 2020; 8:28. PMC: 7397646. DOI: 10.1186/s40364-020-00207-2. View

11.

McEwen B, Morel-Kopp M, Chen W, Tofler G, Ward C . Effects of omega-3 polyunsaturated fatty acids on platelet function in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost. 2013; 39(1):25-32. DOI: 10.1055/s-0032-1333309. View

12.

Fredman G, Van Dyke T, Serhan C . Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol. 2010; 30(10):2005-13. PMC: 2982748. DOI: 10.1161/ATVBAHA.110.209908. View

13.

Dyerberg J, BANG H, Stoffersen E, Moncada S, Vane J . Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis?. Lancet. 1978; 2(8081):117-9. DOI: 10.1016/s0140-6736(78)91505-2. View

14.

Back M . Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis. Pharmacol Ther. 2023; 247:108439. DOI: 10.1016/j.pharmthera.2023.108439. View

15.

Mason R, Libby P, Bhatt D . Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid. Arterioscler Thromb Vasc Biol. 2020; 40(5):1135-1147. PMC: 7176343. DOI: 10.1161/ATVBAHA.119.313286. View

16.

Nelson J, Budoff M, Wani O, Le V, Patel D, Nelson A . EPA's pleiotropic mechanisms of action: a narrative review. Postgrad Med. 2021; 133(6):651-664. DOI: 10.1080/00325481.2021.1921491. View

17.

Watanabe Y, Tatsuno I . Omega-3 polyunsaturated fatty acids focusing on eicosapentaenoic acid and docosahexaenoic acid in the prevention of cardiovascular diseases: a review of the state-of-the-art. Expert Rev Clin Pharmacol. 2020; 14(1):79-93. DOI: 10.1080/17512433.2021.1863784. View

18.

Tsoupras A, Moran D, Byrne T, Ryan J, Barrett L, Traas C . Anti-Inflammatory and Anti-Platelet Properties of Lipid Bioactives from Apple Cider By-Products. Molecules. 2021; 26(10). PMC: 8150973. DOI: 10.3390/molecules26102869. View

19.

Sherratt S, Libby P, Bhatt D, Mason R . A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes. Prostaglandins Leukot Essent Fatty Acids. 2022; 182:102450. DOI: 10.1016/j.plefa.2022.102450. View

20.

Park Y, Harris W . EPA, but not DHA, decreases mean platelet volume in normal subjects. Lipids. 2003; 37(10):941-6. DOI: 10.1007/s11745-006-0984-1. View